相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data
Ruriko Koto et al.
MODERN RHEUMATOLOGY (2021)
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia -
Ichiro Hisatome et al.
CIRCULATION JOURNAL (2021)
Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
Yuji Kumagai et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor
Hiroyuki Fukase et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects
Hiroshi Nakatani et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor
Koichi Omura et al.
DRUG METABOLISM AND PHARMACOKINETICS (2020)
Recent approaches to gout drug discovery: an update
Naoyuki Otani et al.
EXPERT OPINION ON DRUG DISCOVERY (2020)
Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease
Markus Sellmayr et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
Isla S. Mackenzie et al.
LANCET (2020)
Renal stones
Adie Viljoen et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2019)
Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor
Tetsuya Taniguchi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Uric acid regulates NLRP3/IL-1β signaling pathway and further induces vascular endothelial cells injury in early CKD through ROS activation and K+ efflux
Wei Yin et al.
BMC NEPHROLOGY (2019)
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Investigational drugs for hyperuricemia
Hania Shahid et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice
Frederic Preitner et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
Decreased extra-renal urate excretion is a common cause of hyperuricemia
Kimiyoshi Ichida et al.
NATURE COMMUNICATIONS (2012)
A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding
Shintaro Nakayama et al.
DRUG METABOLISM AND DISPOSITION (2009)
Elevated Uric Acid Increases the Risk for Kidney Disease
Rudolf P. Obermayr et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Medical progress: Drug-induced hepatotoxicity
WM Lee
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A new class of CYP2C9 inhibitors: Probing 2C9 specificity with high-affinity benzbromarone derivatives
CW Locuson et al.
DRUG METABOLISM AND DISPOSITION (2003)
分享论文
